Menu

Company profile

Industry Sector: Biotechnology

AfaSci, Inc. is a pre-clinical stage, San Francisco Bay Area-based biotech that discovers and develops peptide and small molecule therapies for unmet needs in the fields of pain and neurology. The company’s current focus has been on developing two therapeutic candidates for the treatment of neuropathic pain and neuroinflammatory pain. These debilitating conditions affect millions of people in the United States and 7-8% of adults worldwide. AfaSci’s two therapeutic candidates are competitively differentiated as novel non-opioid and non-steroidal analgesics. The company also has a drug discovery pipeline focused on Alzheimer’s disease, epilepsy, and sleep disorders.AfaSci’s approach features several competitive advantages:

1)    Two therapeutic candidates for neuropathic and neuroinflammatory pain are ready for IND-enabling studies.

2)    All pre-clinical research has been reviewed and supported by NIH grants, and validated across multiple peer-reviewed publications.

3)    AfaSci has active collaborations with academic institutions including Stanford University, Harvard University, UCLA, UC Davis, and Kansas State University.

4)    The company leverages a proprietary drug discovery platform for more effective target identification and efficient animal testing, in vivo pharmacology, and electrophysiology studies.

AfaSci is now looking to accelerate IND-enabling studies for its two neuropathic and neuroinflammatory pain therapeutic candidates, and seeking opportunities with potential investors and business partners.

 

AfaSci, Inc. is a pre-clinical stage, San Francisco Bay Area-based biotech that discovers and develops peptide and small molecule therapies for unmet needs in the fields of pain and neurology. [AS1]The company’s current focus has been on developing two therapeutic candidates for the treatment of neuropathic pain and neuroinflammatory pain. These debilitating conditions affect millions of people[AS2] in the United States and 7-8% of adults worldwide. AfaSci’s two therapeutic candidates are competitively differentiated as novel non-opioid [AS3]and non-steroidal analgesics. The company also has a drug discovery pipeline focused on Alzheimer’s disease, epilepsy, and sleep disorders.

AfaSci’s approach features several competitive advantages: [AS4]

1)    Two therapeutic candidates for neuropathic and neuroinflammatory pain are ready for IND-enabling studies.

2)    All pre-clinical research has been reviewed and supported by NIH grants, and validated across multiple peer-reviewed publications.

3)    AfaSci has active collaborations with academic institutions including Stanford University, Harvard University, UCLA, UC Davis, and Kansas State University.

4)    The company leverages aproprietary drug discovery platform for more effective target identification and efficient animal testing, in vivo pharmacology, and electrophysiology studies. [AS5]

AfaSci is now looking to accelerate IND-enabling studies for its two neuropathic and neuroinflammatory pain therapeutic candidates, and seeking opportunities with potential investors and business partners.[AS6]


 [AS1]There needs to be a story around over-arching focus against which we can link everything else.

 [AS2]Highlighting potential people impact is much better than market size in $ terms on a page like this.

 [AS3]I took away non-addictive. Can you really say that if you are pre-clinical? (there are non-opioid legal / illegal drugs that are addictive?)

 [AS4]I deleted one bullet that just read as you have regulatory approvals and DEA approval for certain controlled substance. But that isn’t differentiation—just that you are not breaking the law

 [AS5]I don’t think this should be a big focus since investors and partners will really just care about #1, and #2-3 suggest that the work has scientific validity. #4 is just a means to an end from their perspective (I know it is more important for AfaSci internally as a generator of cash flow to sustain the business—but not something to highlight externally that much).

 [AS6]Focus “the ask” on what is your 6-12 month goal. Everything else including end goal of acquisition is secondary.